Novartis

Latest news

• Novartis signs mRNA deal for about $7.8 billion with China's Abogen (opens in a new tab)

  Reuters · Oct 2, 2026

• Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager (opens in a new tab)

  Fierce Biotech · Oct 2, 2026

• 
  Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure? (opens in a new tab)

  Insider Monkey · Sep 28, 2026

• 
  Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? (opens in a new tab)

  Insider Monkey · Sep 26, 2026

• Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines (opens in a new tab)

  Stocktwits · Sep 26, 2026

• A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team (opens in a new tab)

  Yahoo Finance · Sep 25, 2026

• Health Care Roundup: Market Talk (opens in a new tab)

  The Wall Street Journal · Sep 25, 2026

• Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline (opens in a new tab)

  Simply Wall St. · Sep 25, 2026

• Novartis Fends Off Antitrust Suit Over Heart Drug’s FDA Status (opens in a new tab)

  Bloomberg Law News · Sep 24, 2026

• Roche targets Novartis on IgAN market after Phase III win (opens in a new tab)

  Clinical Trials Arena · Sep 24, 2026

• Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis (opens in a new tab)

  Insider Monkey · Sep 24, 2026

• MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests (opens in a new tab)

  Clinical Trials Arena · Sep 24, 2026

• Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? (opens in a new tab)

  Zacks · Sep 24, 2026

• Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof (opens in a new tab)

  GuruFocus.com · Sep 23, 2026

• Amgen price target raised by Jefferies to $410 after positive Sjögren's data (opens in a new tab)

  Proactive · Sep 23, 2026

• Roche, Ionis RNA drug scores in kidney disease study (opens in a new tab)

  BioPharma Dive · Sep 23, 2026

• Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs (opens in a new tab)

  Zacks · Sep 23, 2026

• European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance (opens in a new tab)

  Clinical Trials Arena · Sep 23, 2026

• BoomRay and Novartis sign $900m deal for radioligand therapy (opens in a new tab)

  Pharmaceutical Technology · Sep 23, 2026

• Novartis defeats drug-purchaser lawsuit over delay of Entresto generics (opens in a new tab)

  Reuters · Sep 23, 2026

• Novartis bets up to $900M for radioligand therapy from China’s BoomRay (opens in a new tab)

  BioSpace · Sep 23, 2026

• Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market (opens in a new tab)

  Fierce Biotech · Sep 23, 2026

• AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’ (opens in a new tab)

  The Telegraph · Sep 22, 2026

• European drugmakers call for faster trials, more spending to compete with US, China (opens in a new tab)

  Reuters · Sep 22, 2026

• Novartis secures new radioligand in $900M deal as competition strengthens (opens in a new tab)

  Fierce Biotech · Sep 22, 2026

• Morgan Stanley flags Amgen's edge after heart-drug rival stumbles (opens in a new tab)

  TheStreet · Sep 22, 2026

• Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial (opens in a new tab)

  Insider Monkey · Sep 22, 2026

• Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash (opens in a new tab)

  Investor's Business Daily · Sep 21, 2026

• NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication (opens in a new tab)

  Zacks · Sep 21, 2026

• Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (opens in a new tab)

  Proactive · Sep 21, 2026